Primary Myelofibrosis: Causes, Symptoms, Diagnosis, Treatment, and Prognosis

Primary Myelofibrosis (PMF) is a rare, chronic blood cancer classified as a myeloproliferative neoplasm (MPN). It is characterized by progressive scarring (fibrosis) of the bone marrow, leading to impaired blood cell production and a range of systemic symptoms. PMF can significantly affect quality of life and, in advanced stages, may become life-threatening. However, advances in diagnosis and treatment have improved outcomes for many patients.

This article provides a comprehensive overview of Primary Myelofibrosis, including its causes, clinical features, diagnostic criteria, treatment strategies, and long-term outlook.

~What Is Primary Myelofibrosis?

Primary Myelofibrosis is a clonal stem cell disorder in which abnormal blood-forming stem cells cause excessive production of fibrous tissue in the bone marrow. As normal marrow is replaced by scar tissue, the body compensates by producing blood cells in other organs, such as the spleen and liver — a process known as extramedullary hematopoiesis.

PMF may develop on its own (primary) or evolve from other myeloproliferative neoplasms, such as polycythemia vera or essential thrombocythemia. When it arises independently, it is termed primary myelofibrosis.

~Classification of Myelofibrosis

Primary Myelofibrosis is part of the Philadelphia chromosome–negative myeloproliferative neoplasms, which include:

• Polycythemia Vera (PV)

• Essential Thrombocythemia (ET)

• Primary Myelofibrosis (PMF)

PMF itself may present in two phases:

• Prefibrotic (early) myelofibrosis

• Overt (fibrotic) myelofibrosis

~Causes and Genetic Mutations

Genetic Abnormalities

Most cases of Primary Myelofibrosis are associated with acquired genetic mutations that disrupt normal blood cell regulation:

• JAK2 V617F mutation (approximately 50–60%)

• CALR mutation (20–30%)

• MPL mutation (5–10%)

A small subset of patients lacks all three mutations and is described as triple-negative, which is often associated with a poorer prognosis.

Risk Factors

• Age over 60 years

• Male predominance

• Prior exposure to radiation or toxic chemicals (rare)

• History of other myeloproliferative disorders

PMF is not usually inherited and is not caused by lifestyle factors.

~Pathophysiology of Primary Myelofibrosis

In PMF, mutated stem cells trigger abnormal signaling pathways that promote chronic inflammation and excessive growth factor release. These growth factors stimulate fibroblasts to deposit collagen and reticulin fibers in the bone marrow.

As marrow fibrosis progresses:

• Normal blood cell production declines

• Anemia becomes prominent

• White blood cell and platelet counts may initially rise, then fall

• Blood cell formation shifts to the spleen and liver

This leads to massive splenomegaly and systemic symptoms.

~Signs and Symptoms of Primary Myelofibrosis

Symptoms vary widely depending on disease stage and severity.

Common Symptoms

• Fatigue and weakness

• Shortness of breath

• Weight loss

• Night sweats

• Fever

• Bone pain

Anemia-Related Symptoms

• Pale skin

• Dizziness

• Chest discomfort

• Reduced exercise tolerance

Splenomegaly Symptoms

• Abdominal fullness or pain

• Early satiety

• Left upper quadrant discomfort

• Bloating

Bleeding and Infection

• Easy bruising

• Nosebleeds

• Increased susceptibility to infections due to low white blood cell counts

~Diagnosis of Primary Myelofibrosis

Diagnosis is based on World Health Organization (WHO) criteria, combining clinical, laboratory, and pathological findings.

Blood Tests

• Anemia (most common finding)

• Abnormal white blood cell and platelet counts

• Peripheral blood smear showing:

  • Teardrop-shaped red blood cells (dacrocytes)

  • Immature white blood cells

  • Nucleated red blood cells

Bone Marrow Biopsy

• Increased reticulin and collagen fibrosis

• Abnormal megakaryocytes with atypical nuclei

• Reduced normal hematopoiesis

Genetic Testing

• JAK2, CALR, and MPL mutation analysis

• Additional high-risk mutations (ASXL1, EZH2, SRSF2) may influence prognosis

Imaging Studies

• Ultrasound or CT scan to assess spleen and liver size

~Risk Stratification in Primary Myelofibrosis

Prognosis varies widely among patients. Risk assessment tools help guide treatment decisions.

Common Prognostic Scoring Systems

• International Prognostic Scoring System (IPSS)

• Dynamic IPSS (DIPSS)

• DIPSS-Plus

Factors considered include:

• Age

• Hemoglobin level

• White blood cell count

• Blast percentage

• Constitutional symptoms

• Cytogenetic abnormalities

~Treatment of Primary Myelofibrosis

There is no universal cure for PMF, except for stem cell transplantation in select patients. Treatment focuses on symptom control and improving survival.

Observation and Supportive Care

• Appropriate for low-risk, asymptomatic patients

• Regular monitoring of blood counts and symptoms

Management of Anemia

• Blood transfusions

• Erythropoiesis-stimulating agents

• Androgens (e.g., danazol)

• Immunomodulatory drugs in selected cases

JAK Inhibitors

Target abnormal signaling pathways and reduce symptoms:

• Ruxolitinib

• Fedratinib

• Momelotinib (especially helpful in anemia)

These drugs significantly reduce spleen size and constitutional symptoms but do not reverse fibrosis.

Splenectomy or Radiation Therapy

• Considered in severe splenomegaly unresponsive to medication

• Associated with significant risks and used selectively

Allogeneic Stem Cell Transplantation

• The only potentially curative treatment

• Suitable for younger patients with high-risk disease

• Carries substantial morbidity and mortality risks

~Complications of Primary Myelofibrosis

• Severe anemia

• Recurrent infections

• Thrombotic or bleeding events

• Portal hypertension

• Progression to acute myeloid leukemia (AML)

AML transformation occurs in a minority of patients but carries a poor prognosis.

~Prognosis and Life Expectancy

Prognosis in PMF is highly variable:

• Low-risk patients may live 10–15 years or longer

• High-risk patients may have a median survival of 2–5 years

Outcome depends on:

• Age

• Genetic mutations

• Disease stage

• Response to therapy

Early risk stratification and individualized treatment planning are critical.

~Living With Primary Myelofibrosis

Lifestyle and Self-Care

• Maintain balanced nutrition

• Manage fatigue with rest and gentle activity

• Prevent infections through vaccination and hygiene

• Avoid smoking and excessive alcohol intake

Follow-Up Care

• Regular hematology consultations

• Monitoring for disease progression

• Psychological support for chronic illness management

~Primary Myelofibrosis vs Secondary Myelofibrosis

Feature	Primary Myelofibrosis	Secondary Myelofibrosis
Origin	Develops independently	Evolves from PV or ET
Diagnosis	Initial marrow fibrosis	Prior MPN history
Genetic profile	Often complex	Usually JAK2-driven
Prognosis	Variable	Depends on original disease

~Conclusion

Primary Myelofibrosis is a complex, chronic myeloproliferative neoplasm marked by bone marrow fibrosis, anemia, splenomegaly, and systemic symptoms. While it remains a challenging condition, advances in molecular diagnostics and targeted therapies—particularly JAK inhibitors—have transformed symptom management and improved quality of life. For selected patients, stem cell transplantation offers the possibility of cure.

Early diagnosis, accurate risk assessment, and individualized treatment strategies are essential to optimizing outcomes for patients with Primary Myelofibrosis.